FMP
Financial data for every need
We provide one of the most accurate financial data available on the market. You can get historical prices, fundamental data, insider transactions, and much more that goes back 30 years in history.
Get started
70,000+ Stocks with tons of data
Ready to Unlock Insights?
Welcome to our comprehensive suite of tools designed to streamline your financial data integration process.
API Documentation
Access user-friendly RESTful API documentation suitable for all skill levels.
Detailed endpoint documentation.
Clear request/response examples.
Streamlined navigation.
Ensures clarity/reliability.
API Viewer
Explore endpoints hassle-free with our code-free API Playground.
Interactive data tools.
User-friendly interface.
Download data in CSV/Excel.
Ideal for hands-on exploration.
Stock Prices
Real-time Prices, Historical Data and Indicators.
Stock Fundamentals
Financial Statements, Key Metrics, Stock Financial Scores and more.
Market News
Stock News, Press Releases and Experts Articles.
Company Information
Company Outlook, Market Capitalization, Company Core Information.
Data is collected only from trusted sources
Quality data is key to making accurate, informed decisions. All our data is licensed and sourced from curated third-party data partners, such as the U.S. Securities and Exchange Commission (SEC), Board of Governors of the Federal Reserve System.
See DocumentationFast, accurate, and developer friendly
We provide one of the most accurate data available on the market. We spent years designing endpoints and made them informative, well-documented, and easy to use.
Our API has over 100 endpoints and we are still growing and adding new endpoints every week. Every endpoint is available in JSON format and most of them also in CSV format.
We also provide on demand custom endpoint available for our enterprise plan.
See documentation
Trusted by 100,000+ customers
Join us and get your API key
Latest News
Stay Updated and Harness the Power of Our API with the Latest News!
Dec 23, 2024 2:31 PM - Davit Kirakosyan
Rumble Soars 97% on $775 Million Tether Investment
Rumble Inc. (NASDAQ:RUM) saw its shares skyrocket over 97% intra-day today after securing a $775 million investment from Tether, the company behind the widely used USDT stablecoin. The partnership signals a deepening connection between the cryptocurrency sector and platforms championing free speech,...
Dec 23, 2024 2:28 PM - Davit Kirakosyan
Loop Capital Boosts Microsoft Price Target to $550
Loop Capital analysts raised Microsoft (NYSE:MSFT) price target to $550 from $500, maintaining a Buy rating, citing confidence in the tech giant’s long-term free cash flow (FCF) growth despite significant near-term investments in generative AI. The revised valuation reflects Microsoft’s unique posit...
Dec 23, 2024 2:25 PM - Davit Kirakosyan
Mizuho Raises UGI Corporation Price Target Amid Confidence in Strategic Shift
Mizuho analysts raised their price target for UGI Corporation (NYSE:UGI) to $33 from $30, reiterating an Outperform rating on the stock. The revision reflects growing confidence in UGI’s potential to bridge its valuation gap, driven by strategic initiatives and promising updates from its leadership....
Dec 23, 2024 2:23 PM - Davit Kirakosyan
Datadog's Growth Potential Sparks Price Target Boost to $200
Loop Capital analysts raised their price target for Datadog (NASDAQ:DDOG) to $200 from $160, maintaining a Buy rating on the stock. The increase reflects confidence in the company’s long-term growth trajectory, bolstered by an expanding total addressable market (TAM) and the strategic diversificatio...
Dec 23, 2024 2:20 PM - Davit Kirakosyan
SoundHound AI Price Target Boosted to $26 Amid Surging Demand and Strategic Growth
H.C. Wainwright analysts significantly raised the price target for SoundHound AI (NASDAQ:SOUN) to $26 from $8, reiterating a Buy rating. The upgrade reflects the company’s impressive growth trajectory, fueled by rising demand for its AI-driven services and strategic positioning in diverse industries...
Dec 23, 2024 2:17 PM - Davit Kirakosyan
Exelixis Initiated at Buy with Promising Growth Outlook
Brookline Capital Markets analysts initiated coverage of Exelixis (NASDAQ:EXEL) with a Buy rating, highlighting the biotech company’s strong commercial presence and growth potential across its drug portfolio and pipeline. The firm sees significant upside, projecting Exelixis could reach a valuation ...
Dec 22, 2024 4:00 PM - Alex Lavoie
Aytu BioPharma, Inc. (NASDAQ:AYTU) Financial Performance Analysis
Aytu BioPharma, Inc. (NASDAQ:AYTU) is a pharmaceutical company that focuses on developing and commercializing novel therapeutics. The company operates in a competitive landscape alongside peers like Co-Diagnostics, Inc. (CODX), AIM ImmunoTech Inc. (AIM), iBio, Inc. (IBIO), and OpGen, Inc. (OPGN). Th...
